Treatment of high-risk myelodysplastic syndromes in adults according to European LeukemiaNet recommendations

Abstract

High-risk myelodysplastic syndromes (MDS) are defined by patients who fall into Intermediate-2 or High-risk group categories in the International Prognostic Scoring System or High/Very high in the revised IPSS (R-IPSS). High-risk MDS carry a major risk of progression to acute myeloid leukemia and short survival. Standard therapies include allogeneic stem cell transplantation, induction therapy (AML-like) and hypomethylating agents. This article presents recent European LeukemiaNet recommendations for treatment of high-risk MDS.